S&P 500   4,247.08 (-0.62%)
DOW   33,362.47 (-0.76%)
QQQ   351.91 (-0.65%)
AAPL   169.38 (-1.50%)
MSFT   310.23 (-0.61%)
META   292.79 (-2.06%)
GOOGL   129.16 (+0.46%)
AMZN   125.41 (-0.45%)
TSLA   236.24 (-3.23%)
NVDA   417.59 (-0.36%)
NIO   8.35 (-0.71%)
BABA   85.58 (-0.38%)
AMD   96.78 (+0.85%)
T   14.80 (-1.46%)
F   12.28 (-1.21%)
MU   67.00 (-1.38%)
CGC   0.86 (-7.06%)
GE   110.36 (+0.39%)
DIS   79.32 (-0.91%)
AMC   7.66 (-3.16%)
PFE   32.00 (-1.23%)
PYPL   56.77 (-3.67%)
NFLX   377.45 (-0.47%)
S&P 500   4,247.08 (-0.62%)
DOW   33,362.47 (-0.76%)
QQQ   351.91 (-0.65%)
AAPL   169.38 (-1.50%)
MSFT   310.23 (-0.61%)
META   292.79 (-2.06%)
GOOGL   129.16 (+0.46%)
AMZN   125.41 (-0.45%)
TSLA   236.24 (-3.23%)
NVDA   417.59 (-0.36%)
NIO   8.35 (-0.71%)
BABA   85.58 (-0.38%)
AMD   96.78 (+0.85%)
T   14.80 (-1.46%)
F   12.28 (-1.21%)
MU   67.00 (-1.38%)
CGC   0.86 (-7.06%)
GE   110.36 (+0.39%)
DIS   79.32 (-0.91%)
AMC   7.66 (-3.16%)
PFE   32.00 (-1.23%)
PYPL   56.77 (-3.67%)
NFLX   377.45 (-0.47%)
S&P 500   4,247.08 (-0.62%)
DOW   33,362.47 (-0.76%)
QQQ   351.91 (-0.65%)
AAPL   169.38 (-1.50%)
MSFT   310.23 (-0.61%)
META   292.79 (-2.06%)
GOOGL   129.16 (+0.46%)
AMZN   125.41 (-0.45%)
TSLA   236.24 (-3.23%)
NVDA   417.59 (-0.36%)
NIO   8.35 (-0.71%)
BABA   85.58 (-0.38%)
AMD   96.78 (+0.85%)
T   14.80 (-1.46%)
F   12.28 (-1.21%)
MU   67.00 (-1.38%)
CGC   0.86 (-7.06%)
GE   110.36 (+0.39%)
DIS   79.32 (-0.91%)
AMC   7.66 (-3.16%)
PFE   32.00 (-1.23%)
PYPL   56.77 (-3.67%)
NFLX   377.45 (-0.47%)
S&P 500   4,247.08 (-0.62%)
DOW   33,362.47 (-0.76%)
QQQ   351.91 (-0.65%)
AAPL   169.38 (-1.50%)
MSFT   310.23 (-0.61%)
META   292.79 (-2.06%)
GOOGL   129.16 (+0.46%)
AMZN   125.41 (-0.45%)
TSLA   236.24 (-3.23%)
NVDA   417.59 (-0.36%)
NIO   8.35 (-0.71%)
BABA   85.58 (-0.38%)
AMD   96.78 (+0.85%)
T   14.80 (-1.46%)
F   12.28 (-1.21%)
MU   67.00 (-1.38%)
CGC   0.86 (-7.06%)
GE   110.36 (+0.39%)
DIS   79.32 (-0.91%)
AMC   7.66 (-3.16%)
PFE   32.00 (-1.23%)
PYPL   56.77 (-3.67%)
NFLX   377.45 (-0.47%)
Positive News SentimentPositive News
NASDAQ:KYMR

Kymera Therapeutics (KYMR) Stock Forecast, Price & News

$14.99
-0.34 (-2.22%)
(As of 01:45 PM ET)
Compare
Today's Range
$14.90
▼
$15.72
50-Day Range
$15.25
▼
$23.88
52-Week Range
$14.90
▼
$39.85
Volume
144,019 shs
Average Volume
477,837 shs
Market Capitalization
$830.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$48.10
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Kymera Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
219.0% Upside
$48.10 Price Target
Short Interest
Bearish
13.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($2.55) to ($3.26) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

631st out of 963 stocks

Biological Products, Except Diagnostic Industry

102nd out of 159 stocks

See Top Rated MarketRank™ Stocks Here

KYMR stock logo

About Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

KYMR Price History

KYMR Stock News Headlines

September 18, 2023 | finance.yahoo.com
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
August 31, 2023 | finance.yahoo.com
Industry Analysts Just Upgraded Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts By 19%
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 30, 2023 | msn.com
Morgan Stanley Maintains Kymera Therapeutics (KYMR) Equal-Weight Recommendation
August 29, 2023 | markets.businessinsider.com
The Latest Analyst Ratings for Kymera Therapeutics
August 28, 2023 | finance.yahoo.com
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
August 9, 2023 | msn.com
Kymera Therapeutics - Need More Developments Before Making This A Buy
August 8, 2023 | msn.com
Stifel Maintains Kymera Therapeutics (KYMR) Buy Recommendation
September 27, 2023 | Edge On The Street (Ad)
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
August 7, 2023 | markets.businessinsider.com
Truist Financial Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
August 6, 2023 | seekingalpha.com
Kymera Therapeutics: A Status Update
August 4, 2023 | markets.businessinsider.com
H.C. Wainwright Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)
August 4, 2023 | msn.com
HC Wainwright & Co. Reiterates Kymera Therapeutics (KYMR) Buy Recommendation
August 4, 2023 | markets.businessinsider.com
Expert Ratings for Kymera Therapeutics
August 3, 2023 | finance.yahoo.com
Kymera Therapeutics Announces Second Quarter 2023 Financial Results and Provides a Business Update
July 27, 2023 | finance.yahoo.com
Kymera Therapeutics to Report Second Quarter 2023 Financial Results on August 3
July 9, 2023 | finance.yahoo.com
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
July 1, 2023 | msn.com
Truist Securities Initiates Coverage of Kymera Therapeutics (KYMR) with Buy Recommendation
June 22, 2023 | seekingalpha.com
FDA grants orphan drug status to Kymera blood cancer drug KT-253
June 22, 2023 | finance.yahoo.com
Kymera Therapeutics Receives FDA Orphan Drug Designation for KT-253, a Novel, Highly Potent and Selective MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
June 21, 2023 | benzinga.com
Board Member at Kymera Therapeutics Acquires Company Stock Options Worth 12,000 Shares
June 16, 2023 | fool.com
Kymera Therapeutics (NASDAQ: KYMR)
June 15, 2023 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About Kymera Therapeutics
June 15, 2023 | markets.businessinsider.com
Kymera Therapeutics (KYMR) Gets a Buy from Stifel Nicolaus
June 14, 2023 | finance.yahoo.com
Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials
June 13, 2023 | msn.com
Kymera climbs on data updates for three drug programs
June 12, 2023 | seekingalpha.com
Kymera climbs on data updates for three drug programs (update)
See More Headlines
Receive KYMR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kymera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KYMR Company Calendar

Last Earnings
8/03/2023
Today
9/27/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:KYMR
CUSIP
N/A
CIK
1815442
Web
www.kymeratx.com
Phone
857-285-5300
Fax
N/A
Employees
181
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$48.10
High Stock Price Forecast
$85.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+213.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.76)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-154,810,000.00
Net Margins
-305.01%
Pretax Margin
-305.01%
Return on Equity
-33.17%
Return on Assets
-25.86%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.06
Quick Ratio
7.06

Sales & Book Value

Annual Sales
$46.83 million
Price / Sales
18.14
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$8.93 per share
Price / Book
1.72

Miscellaneous

Outstanding Shares
55,410,000
Free Float
46,175,000
Market Cap
$849.44 million
Optionable
Not Optionable
Beta
1.51
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Bruce L. Booth D.Phil. (Age 49)
    DPHIL, Ph.D., Co-Founder & Chairman
    Comp: $79.19k
  • Dr. Nello Mainolfi M.D. (Age 45)
    Ph.D., Co-Founder, Pres, CEO & Director
    Comp: $975.2k
  • Mr. Bruce N. Jacobs CFAMr. Bruce N. Jacobs CFA
    Chief Financial Officer
  • Dr. Jared A. Gollob M.D. (Age 58)
    Chief Medical Officer
    Comp: $637.81k
  • Dr. Jeremy G. Chadwick Ph.D. (Age 60)
    Chief Operating Officer
  • Mr. Michael J. Todisco (Age 58)
    VP of Accounting & Fin.
  • Mr. Vijay Sabesan (Age 51)
    Sr. VP of Technical Operations
  • Ms. Justine E. Koenigsberg
    VP of Investor Relations
  • Ms. Ellen V. Chiniara Esq. (Age 64)
    J.D., Chief Legal Officer & Corp. Sec.
  • Ms. Melissa Brody
    VP of Bus. Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













KYMR Stock - Frequently Asked Questions

Should I buy or sell Kymera Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kymera Therapeutics in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KYMR shares.
View KYMR analyst ratings or view top-rated stocks.

What is Kymera Therapeutics' stock price forecast for 2023?

9 equities research analysts have issued 12 month target prices for Kymera Therapeutics' shares. Their KYMR share price forecasts range from $31.00 to $85.00. On average, they anticipate the company's stock price to reach $48.10 in the next year. This suggests a possible upside of 213.8% from the stock's current price.
View analysts price targets for KYMR or view top-rated stocks among Wall Street analysts.

How have KYMR shares performed in 2023?

Kymera Therapeutics' stock was trading at $24.96 on January 1st, 2023. Since then, KYMR stock has decreased by 38.6% and is now trading at $15.33.
View the best growth stocks for 2023 here.

When is Kymera Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our KYMR earnings forecast.

How were Kymera Therapeutics' earnings last quarter?

Kymera Therapeutics, Inc. (NASDAQ:KYMR) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.03. The company had revenue of $16.51 million for the quarter, compared to the consensus estimate of $13.93 million. Kymera Therapeutics had a negative trailing twelve-month return on equity of 33.17% and a negative net margin of 305.01%. The company's revenue for the quarter was up 43.4% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.78) earnings per share.

What ETFs hold Kymera Therapeutics' stock?

ETFs with the largest weight of Kymera Therapeutics (NASDAQ:KYMR) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Simplify Propel Opportunities ETF (SURI).

What other stocks do shareholders of Kymera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kymera Therapeutics investors own include Harbor Custom Development (HCDI), Gores Holdings V (GRSVU), FS Development (FSDC), Freeline Therapeutics (FRLN), Duck Creek Technologies (DCT), CureVac (CVAC), Checkmate Pharmaceuticals (CMPI), Burlington Stores (BURL), BigCommerce (BIGC) and KE (BEKE).

When did Kymera Therapeutics IPO?

(KYMR) raised $126 million in an initial public offering on Friday, August 21st 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, BofA Securities, Cowen and Guggenheim Securities served as the underwriters for the IPO.

What is Kymera Therapeutics' stock symbol?

Kymera Therapeutics trades on the NASDAQ under the ticker symbol "KYMR."

Who are Kymera Therapeutics' major shareholders?

Kymera Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.82%), State Street Corp (4.73%), Rock Springs Capital Management LP (2.68%), Wasatch Advisors LP (2.16%), Dimensional Fund Advisors LP (1.52%) and Geode Capital Management LLC (1.45%). Insiders that own company stock include Bruce Booth, Bruce N Jacobs, Bruce N Jacobs, Bvf Partners L P/Il, Jared Gollob, Nello Mainolfi, Richard Chesworth and Venture Fund X LP Atlas.
View institutional ownership trends.

How do I buy shares of Kymera Therapeutics?

Shares of KYMR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kymera Therapeutics' stock price today?

One share of KYMR stock can currently be purchased for approximately $15.33.

How much money does Kymera Therapeutics make?

Kymera Therapeutics (NASDAQ:KYMR) has a market capitalization of $849.44 million and generates $46.83 million in revenue each year. The company earns $-154,810,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis.

How many employees does Kymera Therapeutics have?

The company employs 181 workers across the globe.

How can I contact Kymera Therapeutics?

Kymera Therapeutics' mailing address is 200 Arsenal Yards Blvd. Suite 230, Watertown MA, 02472. The official website for the company is www.kymeratx.com. The company can be reached via phone at 857-285-5300 or via email at ir@kymeratx.com.

This page (NASDAQ:KYMR) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -